Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.
Nanette L A VinckenDeepak M W BalakAndré C KnulstPaco M J WelsingJacob M van LaarPublished in: Rheumatology (Oxford, England) (2022)
Our results indicate that SGCs are frequently prescribed for PsA and psoriasis patients. The occurrence of psoriatic flares appears to be low upon SGC exposure. In patients with a clear indication for SGCs, e.g. in need of rapid anti-inflammatory therapy or bridging of therapies, the use of SGCs should be considered in view of the low risk of skin flaring. It remains of importance to weigh risks for short- and long-term SGC-related side effects in clinical decision making.
Keyphrases
- end stage renal disease
- decision making
- risk assessment
- anti inflammatory
- prostate cancer
- newly diagnosed
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- human health
- stem cells
- ankylosing spondylitis
- atopic dermatitis
- disease activity
- soft tissue
- climate change
- mesenchymal stem cells
- sensitive detection
- hidradenitis suppurativa